Area of research
Oncology · Molecular Biology
Research interest
Research interests include Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses, and Cancer Immunotherapy and Biomarkers.
Management of immune-related cutaneous adverse events with dupilumab
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
The State of Melanoma: Emergent Challenges and Opportunities
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Immune Checkpoint Inhibitor-Associated Optic Neuritis
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Dual MEK/AKT inhibition with trametinib and <scp>GSK</scp>2141795 does not yield clinical benefit in metastatic <scp>NRAS</scp>‐mutant and wild‐type melanoma
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients
A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.
Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+).
Melanoma and immunotherapy bridge 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma